< 2004 News Listings Inotek Pharmaceuticals Appoints Jeffrey Walsh as Vice President of Corporate Development and Commercial Planning BEVERLY, MA May 25, 2004 Inotek Pharmaceuticals Corporation announced today that it has appointed Jeffrey Walsh as Vice President of Corporate Development and Commercial Planning. In his new role, Mr. Walsh will be broadly responsible for building out the commercial aspects of Inotek, specifically in the areas of strategic product planning, business development, and corporate marketing. Mr. Walsh has worked in the pharmaceutical and biotechnology industry for more than 15 years, holding various senior-level positions in worldwide business development, strategic marketing, and corporate finance for SmithKline Beecham (now GlaxoSmithKline), PathoGenesis Corporation (now Chiron Corporation) and EXACT Sciences Corporation. Mr. Walsh has extensive deal experience in various types of strategic partnerships, licensing agreements, and mergers and acquisitions transactions. Mr. Walsh holds a B.A. degree from Yale University and a Masters degree from Northwestern University's Kellogg School of Management. "Jeff will be instrumental in fulfilling a critical commercial role within Inotek as we enter our next phase of growth" commented Dr. Andrew Salzman, Inotek's co-founder, President and CEO. "We will have eight (8) products in clinical development in the next 6-12 months, including one which will likely be in pivotal trials prior to FDA submission. Our biggest challenge going forward will be to set a clear and market-oriented strategy and plan for this diverse pipeline. Jeff's experience in both commercial product planning as well as big pharma and biotech business development will be critical to leading this planning process and to identifying and executing the strategic partnerships that will drive our long term success." About Inotek Pharmaceuticals Corporation Inotek Pharmaceuticals is a research-based pharmaceutical company engaged in the discovery and development of novel, small-molecule therapeutics for the treatment of reperfusion injury, inflammation, and vascular dysfunction. The Company has developed a deep and diverse pipeline of products which are based on industry leading expertise in the area of vascular biology and free radical and oxidant mediated mechanisms of tissue injury, cellular necrosis, and inflammation. The Company has two drug products in Phase II of development, targeting a variety of important critical care conditions. Additionally, the Company has six (6) other products that are expected to enter human clinical trials in the next 6-12 months. Inotek's headquarters and research laboratories are located in Beverly, Massachusetts with overseas clinical and research operations in Israel and Hungary. Contact: Jeffrey T. Walsh Vice President, Corporate Development Inotek Pharmaceuticals Corporation (978) 232-9660 x388
	Copyright ©2007 Rho Capital Partners, Inc.